Astellas Pharma Dirección

Dirección controles de criterios 3/4

El CEO de Astellas Pharma es Naoki Okamura , nombrado en Apr 2023, tiene una permanencia de 4.83 años. compensación anual total es ¥204.00M, compuesta por 34.3% salario y 65.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.002% de las acciones de la empresa, por valor de MX$5.58M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 2.5 años, respectivamente.

Información clave

Naoki Okamura

Chief Executive Officer (CEO)

JP¥204.0m

Compensación total

Porcentaje del salario del CEO	34.3%
Permanencia del CEO	less than a year
Participación del CEO	0.002%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	2.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Naoki Okamura en comparación con los beneficios de Astellas Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	JP¥4b
Sep 30 2023	n/a	n/a	JP¥38b
Jun 30 2023	n/a	n/a	JP¥107b
Mar 31 2023	JP¥204m	JP¥70m	JP¥99b
Dec 31 2022	n/a	n/a	JP¥136b
Sep 30 2022	n/a	n/a	JP¥149b
Jun 30 2022	n/a	n/a	JP¥118b
Mar 31 2022	n/a	n/a	JP¥124b
Dec 31 2021	n/a	n/a	JP¥120b
Sep 30 2021	n/a	n/a	JP¥119b
Jun 30 2021	n/a	n/a	JP¥101b
Mar 31 2021	JP¥236m	JP¥70m	JP¥121b
Dec 31 2020	n/a	n/a	JP¥138b
Sep 30 2020	n/a	n/a	JP¥140b
Jun 30 2020	n/a	n/a	JP¥187b
Mar 31 2020	JP¥232m	JP¥53m	JP¥195b

Compensación vs. Mercado: La compensación total de Naoki($USD1.34M) está por debajo de la media de empresas de tamaño similar en el mercado MX ($USD5.73M).

Compensación vs. Ingresos: La compensación de Naoki ha sido consistente con los resultados de la empresa en el último año.

CEO

Naoki Okamura (61 yo)

less than a year

Permanencia

JP¥204,000,000

Compensación

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Naoki Okamura	President	less than a year	JP¥204.00m	0.0018% MX$ 5.6m
Atsushi Kitamura	Chief Financial Officer	1.3yrs	sin datos	sin datos
Nobue Yasuda	General Manager of Finance & Accounting Department	no data	sin datos	sin datos
Yoshitsugu Shitaka	Chief Scientific Officer & Senior Managing Executive Officer	3.3yrs	sin datos	sin datos
Catherine Levitt	General Counsel	no data	sin datos	sin datos
Katsuyoshi Sugita	Chief People Officer	2.9yrs	sin datos	0.000060% MX$ 182.1k
Stig Ogata	Vice President of Corporate Communications	6yrs	sin datos	sin datos
Collette Taylor	Senior Vice President of Human Resources	no data	sin datos	sin datos
Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	6.1yrs	sin datos	sin datos
Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	7.8yrs	sin datos	sin datos
Jun Kono	Head of Japan Commercial	less than a year	sin datos	sin datos
Andrew Krivoshik	Senior VP & Therapeutic Area and Head for Oncology	5yrs	sin datos	sin datos

3.3yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4503 N se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Naoki Okamura	President	4.8yrs	JP¥204.00m	0.0018% MX$ 5.6m
Katsuyoshi Sugita	Chief People Officer	less than a year	sin datos	0.000060% MX$ 182.1k
Takashi Tanaka	Independent Outside Director	2.8yrs	sin datos	sin datos
Kenji Yasukawa	Chairman of the Board	6.8yrs	JP¥452.00m	0.0071% MX$ 21.5m
Raita Takahashi	Independent Outside Director	3.8yrs	sin datos	sin datos
Eriko Sakurai	Independent Outside Director	2.3yrs	sin datos	sin datos
Mika Nakayama	Independent Outside Director	2.3yrs	sin datos	sin datos
Toru Yoshimitsu	Director	3.8yrs	sin datos	0.0026% MX$ 8.0m
Rie Akiyama	Outside Independent Director	less than a year	sin datos	sin datos
Yoichi Ohno	Outside Independent Director	less than a year	sin datos	sin datos

2.5yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 4503 N no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Astellas Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

High number of new directors

Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023

High number of new directors

Astellas Pharma Inc. Appoints Steve Sabus as Chief Commercial Officer

Recent updates

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

High number of new directors

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol

U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials

Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant

Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial

Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab

Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause

Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S

Third quarter 2023 earnings released: EPS: JP¥26.56 (vs JP¥32.86 in 3Q 2022)

Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023

High number of new directors

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG agreed to acquire Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease

Astellas Pharma Inc. Presents Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium

Astellas Pharma Inc. Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions

Astellas Pharma Inc. to Report Q3, 2023 Results on Feb 06, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3 GLOW Clinical Trial

Astellas Pharma Inc. Appoints Steve Sabus as Chief Commercial Officer

Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment